Content about Matrixx

October 14, 2013

Matrixx Initiatives recently named Lori Norian VP marketing for the Zicam Cold Remedy brand.

BRIDGEWATER, N.J. — Matrixx Initiatives recently named Lori Norian VP marketing for the Zicam Cold Remedy brand. 

Norian previously worked at Unilever and has worked on popular products including Hellman’s, Ragu, Bertolli and Altoids. Norian said she believes her experience translates well to the cold remedy brand, which is targeted primarily to women.

“Knowing how to tap into consumers’ needs and develop resonant messaging and communications strategies is the key to driving further growth for Zicam,” Norian said. 

August 22, 2013

The National Advertising Review Board determined that certain claims made by Matrixx Initiatives for its Zicam Cold Remedy products would not reasonably be understood to mean that use of the products prevents colds.

NEW YORK — The National Advertising Review Board on Wednesday determined that certain claims made by Matrixx Initiatives for its Zicam Cold Remedy products would not reasonably be understood to mean that use of the products prevents colds.

ProPhase Labs initially challenged several advertising claims for Zicam before the National Advertising Division, an investigative unit of the advertising industry’s system of self-regulation. NAD recommended Matrixx discontinue certain claims, which the company agreed to do.

April 5, 2013

The National Advertising Division on Friday recommended that Matrixx Initiatives discontinue advertising claims that suggest its homeopathic Zicam Cold Remedy products prevent users from catching a cold.

NEW YORK — The National Advertising Division on Friday recommended that Matrixx Initiatives discontinue advertising claims that suggest its homeopathic Zicam Cold Remedy products prevent users from catching a cold.

Claims at issue were featured in an advertising campaign that depicted a “Cold Monster” and encouraged treatment with Zicam products at the “pre-cold” stage.

March 12, 2013

Public relations and digital marketing firm Robin Leedy and Associates has added three new clients, the firm said Tuesday.

MOUNT KISCO, N.Y. — Public relations and digital marketing firm Robin Leedy and Associates has added three new clients, the firm said Tuesday.

RL&A said the clients were Matrixx Initiatives, which makes the Zicam family of pre-cold and nasal congestion products; Crosscare, which makes Colief Infant Drops for colic related to transient lactase deficiency; and Cirrus Healthcare Products, which makes EarPlanes air-pressure ear plugs, as well as AquaEars for children. The firm specializes in OTC, health and beauty aids and consumer lifestyle brands marketed to women.

October 29, 2012

ProPhase Labs on Monday again rejected an acquisition proposal from Matrixx Initiatives. Matrixx's latest offer was to acquire ProPhase for $1.60 per share in cash, up from a prior $1.40 per share proposal.

DOYLESTOWN, Pa. — ProPhase Labs on Monday again rejected an acquisition proposal from Matrixx Initiatives. Matrixx's latest offer was to acquire ProPhase for $1.60 per share in cash, up from a prior $1.40 per share proposal. 

October 9, 2012

Matrixx Initiatives on Tuesday announced its second overture to ProPhase Labs with an increased acquisition offer of $1.60 per share.

SKILLMAN, N.J. — Matrixx Initiatives on Tuesday announced its second overture to ProPhase Labs with an increased acquisition offer of $1.60 per share. The revised offer represents a premium of 51.7% over the 30-day average closing price of ProPhase's stock and a 53.7% premium to ProPhase's average closing price over the 12 months preceding Sept. 6 — the day ProPhase's former chairman and CEO, Guy Quigley, filed a Schedule 13D announcing Matrixx's purchase of a three-year option to acquire 1.45 million shares of ProPhase common stock.

September 17, 2012

ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

DOYLESTOWN, Pa. — ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

ProPhase stock was up 20 cents to $1.39 in mid-afternoon trading.

Matrixx is the owner of the Zicam brand of cold and allergy products and is a direct competitor to ProPhase's Cold-Eeze Cold Remedy product line.

June 8, 2011

With former Wyeth executive Dennis O’Donnell at the helm, Matrixx Initiatives is making a headquarter transition from Phoenix to here in New Jersey, according to a story published in the Arizona Republic earlier this week.

SKILLMAN, N.J. — With former Wyeth executive Dennis O’Donnell at the helm, Matrixx Initiatives is making a headquarter transition from Phoenix to here in New Jersey, according to a story published in the Arizona Republic earlier this week.

The company, however, will maintain offices in Arizona, the report stated.

February 18, 2011

NEW YORK — The second half of the 2010-2011 cough-cold-flu season actually may realize greater sales of symptom relievers than last year, judging from the four weeks ended Dec. 26. According to Matrixx president and CEO Bill Hemelt, sales of remedies were on the rise in those four weeks. Hemelt noted that the total cough-cold category was 5% higher than the same period last year and growing. 


January 21, 2011

Matrixx Initiatives on Friday provided a summary of the ongoing "go-shop" process initiated by the company after Wonder Holdings proposed a merger agreement. The “go-shop” process is scheduled to run through Jan. 22.

SCOTTSDALE, Ariz. — Matrixx Initiatives on Friday provided a summary of the ongoing "go-shop" process initiated by the company after Wonder Holdings proposed a merger agreement. The “go-shop” process is scheduled to run through Jan. 22.

January 21, 2011

Cough-cold supplier Matrixx on Thursday credited tough comparisons against the prior season’s high pre-season inventory purchases by retailers due to the publicity of the H1N1 flu outbreak for the lower level of sales for the quarter ended Dec. 31, 2010.

SCOTTSDALE, Ariz. — Cough-cold supplier Matrixx on Thursday credited tough comparisons against the prior season’s high pre-season inventory purchases by retailers due to the publicity of the H1N1 flu outbreak for the lower level of sales for the quarter ended Dec. 31, 2010.

The company reported net sales of $20.3 million, down 29%. However, a lift in late December cough-cold illness rates holds promise for the second half of the season.

December 14, 2010

Matrixx Initiatives on Tuesday announced that it has entered into a definitive merger agreement to be acquired by affiliates of private equity firm H.I.G. Capital.

SCOTTSDALE, Ariz. — Matrixx Initiatives on Tuesday announced that it has entered into a definitive merger agreement to be acquired by affiliates of private equity firm H.I.G. Capital.

The board of directors of Matrixx unanimously has approved the merger agreement. Under the terms of the merger agreement, affiliates of H.I.G. will commence a tender offer to purchase all of the outstanding shares for approximately $75.2 million.

October 25, 2010

Matrixx Initiatives on Monday reported a decline of 17% in net sales to $21.3 million...

SCOTTSDALE, Ariz. Matrixx Initiatives on Monday reported a decline of 17% in net sales to $21.3 million for the company’s second quarter ended Sept. 30. The decline, Matrixx president and CEO Bill Hemelt explained to analysts Tuesday morning, represented a course correction of sorts. The sales decline was “due to lower upfront buys by retailers,” Hemelt said. Last year, all of the hype around H1N1 drove retailers to heavily stock in cough-and-cold supplies.

September 26, 2010

The pharmaceutical industry earlier this month weighed in on the case “Matrixx Initiatives vs. James...

WASHINGTON —The pharmaceutical industry earlier this month weighed in on the case “Matrixx Initiatives vs. James Siracusano and NECA-IBEW Pension Fund.”

August 29, 2010

Industry lobbyists last week weighed in on a Ninth Circuit ruling that allowed for a...

WASHINGTON Industry lobbyists last week weighed in on a Ninth Circuit ruling that allowed for a class action lawsuit to proceed against Matrixx Initiatives because that company failed to disclose adverse event reports to its shareholders.

 

August 22, 2010

There are three factors that will help shape the upcoming cough-cold season: supply chain, illness...

June 6, 2010

Matrixx Initiatives recently introduced a new line of Zicam products—Cold Remedy Plus—a multi-ingredient formulation that...

May 18, 2010

Matrixx Initiatives on Wednesday named William Barba VP finance and accounting and treasurer effective May 6....

March 16, 2010

Matrixx Initiatives recently introduced a new line of Zicam products — Cold Remedy Plus, a...

PHOENIX Matrixx Initiatives recently introduced a new line of Zicam products — Cold Remedy Plus, a multi-ingredient formulation that both reduces the duration of the common cold and helps relieve the symptoms of someone who already has a cold.

The Cold Remedy Plus products, cherry-flavored Liqui-Loz and cherry-flavored Zavors, retail for a suggested $11.59. Two mint flavors — including a rapid melt and oral mist — will launch in the fall.